Public Sector Pension Investment Board Acquires 30,989 Shares of Artivion, Inc. $AORT

Public Sector Pension Investment Board increased its stake in Artivion, Inc. (NYSE:AORT) by 23.7% during the third quarter, according to its most recent filing with the SEC. The fund owned 161,970 shares of the company’s stock after buying an additional 30,989 shares during the quarter. Public Sector Pension Investment Board’s holdings in Artivion were worth $6,858,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its holdings in Artivion by 22.8% during the second quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock worth $20,062,000 after buying an additional 119,634 shares during the last quarter. Invesco Ltd. grew its position in shares of Artivion by 40.8% during the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after acquiring an additional 139,370 shares during the period. Kennedy Capital Management LLC increased its stake in shares of Artivion by 20.8% during the 2nd quarter. Kennedy Capital Management LLC now owns 367,762 shares of the company’s stock worth $11,437,000 after purchasing an additional 63,205 shares during the last quarter. Peregrine Capital Management LLC increased its stake in shares of Artivion by 1.8% during the 2nd quarter. Peregrine Capital Management LLC now owns 316,697 shares of the company’s stock worth $9,849,000 after purchasing an additional 5,473 shares during the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Artivion by 0.5% in the 3rd quarter. Principal Financial Group Inc. now owns 259,750 shares of the company’s stock worth $10,998,000 after purchasing an additional 1,244 shares during the period. Institutional investors own 86.37% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Jean F. Holloway sold 7,315 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $45.30, for a total transaction of $331,369.50. Following the completion of the transaction, the senior vice president owned 156,093 shares of the company’s stock, valued at approximately $7,071,012.90. The trade was a 4.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Marshall S. Stanton sold 47,376 shares of the firm’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $45.04, for a total transaction of $2,133,815.04. Following the completion of the sale, the senior vice president directly owned 44,753 shares in the company, valued at $2,015,675.12. This represents a 51.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 105,460 shares of company stock valued at $4,751,927 in the last ninety days. Corporate insiders own 8.10% of the company’s stock.

Artivion Stock Performance

Artivion stock opened at $36.50 on Wednesday. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $48.25. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $1.73 billion, a PE ratio of 182.51 and a beta of 1.59. The firm’s 50 day simple moving average is $43.30 and its 200 day simple moving average is $43.02.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. The firm had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. Artivion’s revenue for the quarter was up 19.2% compared to the same quarter last year. As a group, analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on AORT. Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, January 21st. Canaccord Genuity Group lowered their price target on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Artivion in a report on Monday, February 2nd. Citizens Jmp boosted their target price on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Finally, Oppenheimer restated an “outperform” rating and set a $50.00 target price on shares of Artivion in a research report on Friday, November 7th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $48.97.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.